Palisade Bio Inc
NASDAQ:PALI

Watchlist Manager
Palisade Bio Inc Logo
Palisade Bio Inc
NASDAQ:PALI
Watchlist
Price: 0.7901 USD -10.05% Market Closed
Market Cap: 3.8m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

PALI doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of PALI.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PALI Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
8
Median 3Y
0
Median 5Y
0
Industry
2.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-11
Industry
22
Forward
-0.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-19.3
Industry
17.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-18.2
Industry
24
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
90
vs Industry
79
Median 3Y
3
Median 5Y
9.7
Industry
2.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
2
Median 3Y
0
Median 5Y
0
Industry
2.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
More Details
0.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.4
vs History
3
vs Industry
55
Median 3Y
-1.8
Median 5Y
-16.7
Industry
13.2
More Details
0.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.4
vs History
3
vs Industry
52
Median 3Y
-1.8
Median 5Y
-16.7
Industry
16.7
Forward
0.5
More Details
0.5
EV/OCF
EV/OCF
Enterprise Value to OCF
0.5
vs History
3
vs Industry
56
Median 3Y
-2.1
Median 5Y
-18.3
Industry
15.6
More Details
0.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.5
vs History
3
vs Industry
42
Median 3Y
-2.1
Median 5Y
-18.3
Industry
17.8
More Details
131.1
EV/IC
EV/IC
Enterprise Value to IC
131.1
vs History
57
vs Industry
3
Median 3Y
84.4
Median 5Y
190.7
Industry
2
More Details

Multiples Across Competitors

PALI Competitors Multiples
Palisade Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Palisade Bio Inc
NASDAQ:PALI
3.8m USD 0 -0.3 0.4 0.4
US
Eli Lilly and Co
NYSE:LLY
592.4B USD 11.1 42.9 25.6 27.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
417B USD 4.6 18.4 14 18.4
CH
Roche Holding AG
SIX:ROG
196B CHF 3.2 23.7 8.9 10.4
UK
AstraZeneca PLC
LSE:AZN
169.4B GBP 4 27.5 112.5 168.2
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 16.5 10 13.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 12.9 9.5 10.5
US
Merck & Co Inc
NYSE:MRK
203B USD 3.2 12.4 8 9.5
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
139.7B USD 2.2 13 7.4 10.1
P/S Multiple
Revenue Growth P/S to Growth
US
Palisade Bio Inc
NASDAQ:PALI
Average P/S: 69.4
Not Available 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
11.1
23%
0.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
4.6
5%
0.9
CH
Roche Holding AG
SIX:ROG
3.2
4%
0.8
UK
AstraZeneca PLC
LSE:AZN
4
7%
0.6
CH
Novartis AG
SIX:NOVN
4.1
5%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
4.6
13%
0.4
US
Merck & Co Inc
NYSE:MRK
3.2
4%
0.8
IE
E
Endo International PLC
LSE:0Y5F
79.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.2
-1%
N/A
P/E Multiple
Earnings Growth PEG
US
Palisade Bio Inc
NASDAQ:PALI
Average P/E: 20.9
Negative Multiple: -0.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.9
49%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.4
27%
0.7
CH
Roche Holding AG
SIX:ROG
23.7
32%
0.7
UK
AstraZeneca PLC
LSE:AZN
27.5
36%
0.8
CH
Novartis AG
SIX:NOVN
16.5
16%
1
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
18%
0.7
US
Merck & Co Inc
NYSE:MRK
12.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Palisade Bio Inc
NASDAQ:PALI
Average EV/EBITDA: 394
0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
25.6
30%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14
8%
1.8
CH
Roche Holding AG
SIX:ROG
8.9
5%
1.8
UK
AstraZeneca PLC
LSE:AZN
112.5
10%
11.3
CH
Novartis AG
SIX:NOVN
10
5%
2
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
13%
0.7
US
Merck & Co Inc
NYSE:MRK
8
7%
1.1
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Palisade Bio Inc
NASDAQ:PALI
Average EV/EBIT: 1 700.3
0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.8
33%
0.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.4
14%
1.3
CH
Roche Holding AG
SIX:ROG
10.4
6%
1.7
UK
AstraZeneca PLC
LSE:AZN
168.2
23%
7.3
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.5
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
9%
1.1

See Also

Summary
PALI intrinsic value, competitors valuation, and company profile.
DCF Valuation
PALI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PALI stock valuation using valuation multiples.
Wall Street Estimates
PALI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PALI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 274,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.